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An increasing number of studies have suggested that certain cases of iatrogenic 
Creutzfeldt-Jakob disease (iCJD) that harbor significant β-amyloid (Aβ) pathology are the 
result of aggregated Aβ transmission to patients during the same procedure that caused prion 
disease [2, 4, 7, 8, 11, 13, 17]. The source of iatrogenic contamination has been observed 
both for human growth hormone infusions and dura mater grafts, arguing against a treatment 
specific effect. Intriguingly, recent work has also observed suspected Aβ pathology 
transmission in post-mortem samples that received growth hormone treatments but did not 
develop CJD [17]. Yet another study suggested that neurosurgery with Aβ-contaminated 
tools can transmit Aβ pathology and lead to intracerebral hemorrhage [12]. These findings 
have been debated in the context of whether Aβ pathology is truly transmissible and whether 
Alzheimer’s disease could subsequently develop. 
It is well known that aggregated Aβ can nucleate the misfolding and aggregation of 
naïve Aβ monomers both in vitro and in vivo, in a process termed seeding [15, 20]. Thus, it 
appears plausible that exogenous Aβ seeds could induce pathology in human subjects. 
However, it has been reported that the cellular prion protein, PrPC, can bind different Aβ 
species, especially oligomers [3, 14]. Furthermore, conflicting reports have suggested that 
infectious prions (PrPSc) can exacerbate Aβ deposition at a time point where plaques are 
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already present, with both pathologies working synergistically, but also that misfolded Aβ 
can actually interfere with prion pathogenesis [16, 18, 19]. Given these findings, it is 
important to consider that PrPSc inoculations could influence Aβ pathology, but the role of 
PrPSc in initiating cerebral β-amyloidosis is still unclear. To this end, we inoculated APP 
transgenic mice on a PrPC wildtype or heterozygous background with infectious PrPSc prions 
to investigate whether PrPSc alters the onset of Aβ pathology. 
APP23 mice expressing human amyloid precursor protein (APP) with a Swedish 
mutation (KM670/671NL) were intracerebrally inoculated (hippocampus, bregma: 2.5 mm 
posterior; +/-2.0 mm lateral; 1.8 mm ventral) with infectious RML-PrPSc or wildtype (WT) 
brain extracts (1% w/v) prepared from RML-PrPSc infected or healthy CD1 mice respectively, 
using the Precellys system (5500 rpm, 2x20 sec, Bertin Instruments) (Fig. 1a, Supplemental 
Methods). All PrPSc-inoculated mice developed terminal prion disease and were sacrificed 
after 176 days post injection (median). Histological analysis with Hematoxylin & Eosin and 
SAF84 (PrPSc, 1:250) revealed that brains displayed typical vacuolation (spongiosis) and PrP-
immunoreactive deposits in sick animals, which was not detectable in WT-injected animals 
of the same age (Fig. 1a). Using an in-house pan-Aβ antibody (CN6, 1:1000) (Supplemental 
Methods), no induced Aβ pathology was detected in the hippocampus of PrPSc prion-injected 
animals while, conversely, the injection of minimal Aβ seeds and a similar incubation period 
does yield Aβ deposition as demonstrated previously [20]. 
Given that the incubation period of the suggested transmission of human Aβ 
pathology is 10 to 40 years for both transmission via contaminated dura grafts and growth 
hormone [2, 4, 8, 10, 11], we hypothesized that the incubation period in our mouse model 
may not be long enough to detect induced Aβ pathology caused by PrPSc prions. Thus, 
APP23 mice were crossed to a Prnp-null line to produce PrPC heterozygous mice (APP23-
PrP+/-), which is known to increase the prion incubation period until terminal sickness [1, 6]. 
Indeed, APP23-PrP+/- mice injected with PrPSc prions survived an extra 69 days after 
intrahippocampal inoculation as described above (median survival: 245 days post injection) 
before being sacrificed due to prion disease with the expected PrPSc-positive staining using 
SAF84 (Fig. 1b). Nevertheless, none of the animals injected with PrPSc prions presented with 
detectable seeded Aβ deposition after staining sections for Aβ (CN6) (Fig. 1b). In parallel, 
APP23-PrP+/- mice were also inoculated with brain extracts prepared from aged APP23 Aβ-
laden brains homogenized with the Precellys system as above (10% w/v) followed by a 3000 
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g centrifugation (5 min). All Aβ injected animals showed obvious induced Aβ pathology as 
expected [15, 20] (Fig. 1b). 
 The potential of Aβ pathology transmission under specific circumstances in humans is 
interesting both from a basic biology and human health perspective [2, 4, 7, 8, 10-13, 17]. 
However, given that these human studies are observational, there are questions on the 
mechanism behind the increased Aβ deposition. We have found that intrahippocampal 
inoculations of infectious RML prions into APP23 transgenic mice caused prion disease but 
did not induce Aβ pathology in the hippocampus after long incubation periods that are 
sufficient to detect seeded Aβ pathology caused by nanomolar amounts of Aβ (one seeding 
unit) [20]. This argues against a direct cross-seeding effect of PrPSc prions on Aβ or an 
indirect effect of prion disease leading to Aβ pathology. This conclusion is supported by the 
recent report that patients who received growth hormone treatments but did not have prion 
disease still contained significant Aβ pathology and other instances suggesting Aβ pathology 
in prion disease patients is an age-related phenomenon [9, 17]. 
 It is worth noting that, although PrPSc did not induce Aβ pathology before terminal 
prion disease, these inoculations were intracerebral and were meant to provide a model 
system for dura mater grafting or for contaminated surgical instruments. Instances of Aβ 
pathology after peripheral growth hormone treatment in humans with iCJD could be caused 
by Aβ seeds in the growth hormone extract traveling to the brain similar to studies in APP 
transgenic mice [2, 4, 5, 11, 17]. However, it cannot be excluded that a peripheral prion 
infection indirectly influences Aβ pathology [18], and thus mechanistically would contrast 
intracerebral exposure. It is also important to consider that a different PrPSc prion strain may 
harbor Aβ pathology inducing activity. 
From our work, we can conclude that misfolded Aβ introduced during treatment may 
be responsible for induction of Aβ pathology in these human cases as opposed to being the 
by-product of iCJD prion infection. Future work will need to determine whether cases of Aβ 
pathology transmission could eventually develop into clinical Alzheimer’s disease. 
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Fig. 1. RML-PrPSc inoculations into APP23 transgenic mice do not induce Aβ deposition. (a) 
APP23 mice were injected with either RML PrPSc (n=5; 4 males, 1 female) or a WT control 
brain extract (n=5; 3 males, 2 females) and monitored until RML-injected animals became 
sick (median survival: 176 d), at which time point all animals were sacrificed. Representative 
histological stains for Hematoxylin-Eosin (H&E), PrPSc (SAF84) and Aβ (CN6) are 
presented. None of the RML PrPSc (0/5) or WT inoculated (0/5) APP23 mice revealed any 
detectable Aβ deposits in the hippocampus. H&E, PrPSc scale bars=100 μm; Aβ scale 
bar=200 μm. (b) APP23 mice heterozygous for PrPC (APP23-PrP+/-) were injected with either 
RML PrPSc (n=7; 4 males, 3 females), WT control (n=6; 4 males, 2 females) or Aβ seeding 
extract (n=6; 3 males, 3 females). Mice were monitored until RML-injected animals became 
sick, then all animals were sacrificed (median survival: 245 d). Representative histological 
stainings of PrPSc (SAF84) and Aβ (CN6) are presented. None of the RML-PrPSc (0/7) or 
WT-inoculated (0/6) APP23-PrP+/- mice revealed any detectable induced Aβ deposits 
whereas all Aβ seed-inoculated (6/6) APP23-PrP+/- mice showed induced Aβ deposition. 
PrPSc scale bar=100 μm; Aβ scale bar=200 μm. 
